OpenAI Launches Rosalind Biodefense to Expand AI Use in Pandemic Preparedness
29 May 2026
Rosalind Biodefense gives vetted developers and selected public-health partners controlled access to GPT-Rosalind for pandemic preparedness.
OpenAI Launches GPT-Rosalind for Life Sciences Research
16 April 2026
OpenAI has launched GPT-Rosalind, a life sciences AI model for biological research, drug discovery, and tool-heavy scientific workflows.
OpenAI and Gates Foundation Announce $50M Horizon 1000 for Primary Healthcare in Africa
20 January 2026
Horizon 1000 is a $50 million OpenAI–Gates Foundation initiative to scale AI tools for intake, triage and follow-up in 1,000 African clinics by 2028.
Anthropic Launches Claude for Healthcare: Safety Rules & New Tools
11 January 2026
Anthropic has unveiled Claude for Healthcare and Life Sciences, a specialized AI suite powered by the new Claude Opus 4.5 model. Unlike OpenAI’s patient-focused ChatGPT Health, this offering prioritizes administrative efficiency and safety, mandating professional review for high-risk outputs while utilizing “connectors” to integrate with Medidata, CMS databases, and PubMed to automate complex workflows.
OpenAI Launches ChatGPT Health, a Dedicated Hub for Medical Records and Wellness Data
7 January 2026
ChatGPT Health is OpenAI’s new health-focused feature, linking medical records and wellness data to support more contextual, personalized health assistance.
AI Model Delphi-2M Predicts Disease Risks Across 1,258 Conditions Over 20 Years
17 September 2025
Delphi-2M, trained on UK and Danish datasets, predicts disease risks for 1,258 conditions up to 20 years in advance, supporting preventive healthcare planning.
Microsoft’s MAI-DxO Outperforms Doctors in Diagnosing Complex Cases
3 July 2025
Microsoft’s MAI-DxO surpassed physicians in diagnosing complex NEJM cases with 85.5% accuracy. Transparent, efficient, and scalable—AI medicine enters a new era.
Google DeepMind’s AlphaGenome Decodes Genetic Mutations with AI
28 June 2025
AlphaGenome, DeepMind’s latest AI, simulates how mutations impact gene regulation, enabling breakthrough research in genomics, cancer, and synthetic biology.
U.S. FDA Launches Agency-Wide AI Tool “Elsa” to Optimize Performance
2 June 2025
Elsa, the FDA’s internal AI assistant, was deployed across the agency to improve efficiency. Staff say it’s rushed, flawed, and not ready for regulatory use.
